Adragos Pharma, an internationally recognized contract development and manufacturing organization (CDMO) based in Munich, Germany, has acquired Baccinex, a Swiss expert known for its proficiency in aseptic fill-finish manufacturing. This acquisition significantly bolsters Adragos’ capabilities in sterile manufacturing and signifies a crucial advancement in expanding its worldwide network.
Located in Courroux, Jura, Switzerland, Baccinex boasts over two decades of experience in aseptic fill-finish processes, handling both liquid and lyophilized vials. Operating out of an EU-GMP and US FDA-certified facility, Baccinex excels in providing clinical trial supplies and small-to-medium scale commercial production with exceptional quality and dependability for its pharmaceutical partners.
Dr. Ursula Bausch, the founder and CEO of Baccinex, expressed her enthusiasm for the collaboration: “Becoming part of Adragos Pharma initiates a new era for Baccinex. Our mutual dedication to quality, innovation, and customer-oriented solutions fosters an exciting partnership that positions us to offer even greater benefits to our clients around the globe.”
Dr. Andreas Raabe, the founder and CEO of Adragos Pharma, stated: “Acquiring Baccinex is a landmark achievement for Adragos. Baccinex’s established proficiency in sterile liquid and lyophilization, along with its operational prowess, elevates our capability to furnish integrated solutions from development to market supply. This acquisition fortifies our role as a premier global partner in high-quality pharmaceutical production.”
Dr. Ursula Bausch will retain her role as CEO of Baccinex, ensuring smooth operations while utilizing her vast experience in sterile manufacturing. She will also continue as a shareholder, highlighting her commitment to the company’s ongoing growth within Adragos.
The acquisition of Baccinex aligns perfectly with Adragos’ strategic vision of building a world-class manufacturing network, delivering bespoke solutions tailored to meet the dynamic requirements of its clientele.
Pestalozzi Attorneys at Law provided legal guidance to Adragos Pharma. Capitalmind Investec served as the M&A advisor, whereas Kellerhals Carrard was the legal advisor to Dr. Ursula Bausch.
Details of the transaction remain undisclosed.
Adragos Pharma, a swiftly growing global CDMO, operates out of Munich, Germany. With a presence spanning six locations across Europe and Japan, Adragos delivers comprehensive pharmaceutical services, supporting clients through all stages from development to commercial production.
Based in Switzerland, Baccinex is a CDMO adept in sterilized fill-finish services for liquid and lyophilized vials. With a rich history of over 20 years, Baccinex runs its EU-GMP and US FDA-certified facility in Courroux, Jura, Switzerland, offering top-tier pharmaceutical solutions tailored to meet clients’ diverse needs.